BTG varicose vein treatment accepted for review by FDA
BTG, an international specialist healthcare company, has announced that the US Food & Drug Administration (FDA) has accepted the new drug application for the group's Varisolve product.
BTG, an international specialist healthcare company, has announced that the US Food & Drug Administration (FDA) has accepted the new drug application for the group's Varisolve product.
The application for the varicose vein treatment was submitted on February 4th of this year, and has been accepted for a full review by the FDA.
Based on standard review timelines, BTG said it anticipates potential US approval and launch of the product during the first half of 2014.
NR